Welcome to our dedicated page for IGM Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on IGM Biosciences stock.
IGM Biosciences, Inc. (Nasdaq: IGMS) is a clinical-stage biotechnology company dedicated to transforming the treatment landscape for cancer, infectious diseases, and autoimmune and inflammatory diseases. At the core of the company’s innovation is its proprietary IgM antibody technology platform, which is optimized for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines.
IGM Biosciences’ leading product candidate is IGM-2323, a bispecific IgM antibody currently in Phase 1 clinical trials aiming to treat patients with B cell non-Hodgkin lymphoma (NHL) and other B cell malignancies. Another promising candidate, IGM-8444, targets death receptor 5 (DR5) proteins and is being developed for the treatment of colorectal cancer. The company is also advancing IGM-7354, a bispecific IgM antibody designed to deliver interleukin-15 cytokines to PD-L1 expressing cells in patients with solid and hematologic malignancies.
IGM Biosciences has formed strategic collaborations to enhance its research and development efforts. These include partnerships with Atreca Inc. and BeiGene Ltd. to identify and develop novel IgM and IgA antibodies against SARS-CoV-2, and a strategic research collaboration with AbCellera to discover IgM antibodies. Additionally, IGM has an exclusive worldwide collaboration agreement with Sanofi to develop and commercialize IgM antibody agonists targeting oncology, immunology, and inflammation.
The financial outlook for IGM remains robust. For the 2023 fiscal year, the company projected operating expenses between $275 million and $285 million, including a non-cash stock-based compensation expense of around $50 million. IGM expects to end 2023 with over $325 million in cash and investments, ensuring its operations are funded into the second half of 2025.
Recent updates highlight significant progress in IGM’s pipeline. Notably, the company continues to advance candidates such as Imvotamab for severe systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
IGM’s commitment to innovation is demonstrated by its ongoing efforts to develop novel therapies that meet unmet medical needs. With a robust pipeline and strategic partnerships, IGM Biosciences aims to make significant strides in the biopharmaceutical industry.
IGM Biosciences announced its participation at the 2021 Cantor Virtual Global Healthcare Conference scheduled for September 29, 2021, at 3:20 p.m. EDT. The live presentation will be accessible via a webcast on the company’s website, specifically in the Investors section. IGM Biosciences is focused on developing engineered IgM antibodies and has created a proprietary platform since its establishment. A replay of the event will be available for 90 days post-presentation.
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology firm, announced participation in three investor conferences: the Citi 16th Annual BioPharma Virtual Conference on September 9, the Morgan Stanley 19th Annual Global Healthcare Conference on September 13 at 2:45 p.m. EDT, and Baird’s 2021 Global Consumer, Technology & Services Conference on September 14 at 2:35 p.m. EDT. A live webcast of the Morgan Stanley chat will be available on the company’s website, with a replay archived for 90 days.
IGM Biosciences reported its Q2 2021 financial results, revealing a net loss of $38.7 million, or $1.16 per share, compared to a loss of $18.8 million, or $0.62 per share in Q2 2020. Cash and investments totaled $301.8 million at the end of June 2021, a decline from $366.3 million at year-end 2020. The company is making progress in its pipeline, with ongoing trials for IGM-2323 and IGM-8444. Additionally, it plans to file an IND for IGM-7354 this year and expects to end 2021 with over $200 million in cash and investments.
IGM Biosciences (Nasdaq: IGMS) announced the appointment of Dr. Chris H. Takimoto as Chief Medical Officer, effective today. Dr. Takimoto brings over 30 years of oncology expertise, previously serving at Gilead Sciences. He will oversee IGM’s clinical pipeline of engineered IgM antibodies, following Dr. Daniel S. Chen's transition to a consulting role. CEO Fred Schwarzer praised Dr. Takimoto's extensive experience in clinical development. IGM aims to leverage its advanced IgM technology to enhance therapeutic applications across oncology and other fields.
IGM Biosciences announced plans to advance IGM-6268, the first intranasally administered IgM antibody, into clinical trials in Q3 2021. This new candidate targets COVID-19 and builds on findings published in Nature, highlighting its superior neutralization potency against SARS-CoV-2 variants compared to IgG antibodies. Preclinical studies indicate that IGM-6268 offers significant protective effects with a promising safety profile. The technology platform's expansion into infectious diseases marks a key development for IGM Biosciences in combating viral challenges.
IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 1:00 p.m. EDT. A live webcast can be accessed via the company's 'Events and Presentations' page on its website, with a replay available for 90 days post-event. IGM focuses on developing engineered IgM antibodies for various diseases, aiming to overcome manufacturing challenges since 2010.
IGM Biosciences (Nasdaq: IGMS), a biotechnology company focused on engineered IgM antibodies, announced that CEO Fred Schwarzer will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 1:55 p.m. EDT. The event will be held virtually. A live webcast will be accessible on the company’s website, with a replay available for 90 days post-event. This forum highlights IGM's progress since 2010 in overcoming challenges in IgM antibody development.
IGM Biosciences (Nasdaq: IGMS) reported Q1 2021 net loss of $31.6 million, up from $17.6 million in 2020. Cash and investments decreased to $331.7 million from $366.3 million in Q4 2020. The company anticipates a recommended Phase 2 dose for IGM-2323 and expects to report initial data from its Phase 1 trial of IGM-8444 later this year. IGM also plans to file an IND for IGM-7354. Despite rising R&D expenses ($23.6 million vs. $14.6 million), the company maintains a full-year operating expense guidance of $175-$185 million, with expected cash reserves over $200 million by year-end.
IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will speak at the Truist Securities Life Sciences Summit on May 4, 2021, at 4:20 p.m. EDT. The summit will occur virtually, and interested parties can access a live webcast on the company’s website. A replay will be available for 90 days post-event. IGM Biosciences focuses on developing engineered IgM antibodies for treating various diseases, leveraging its proprietary technology platform to overcome challenges in IgM antibody production.
IGM Biosciences appointed George A. Gauthier as Chief Commercial Officer, leveraging 20 years of global life sciences experience. Previously at Genentech, Gauthier led strategies for breast and gynecological cancers. CEO Fred Schwarzer highlighted Gauthier's role in advancing the commercialization of IGM's engineered IgM antibodies. IGM focuses on overcoming the challenges in IgM antibody development, aiming to utilize their unique properties in therapeutic applications. The company continues its journey in clinical-stage biotechnology, committed to innovative patient treatments.
FAQ
What is the current stock price of IGM Biosciences (IGMS)?
What is the market cap of IGM Biosciences (IGMS)?
What is IGM Biosciences, Inc.?
What are the key product candidates of IGM Biosciences?
What diseases is IGM Biosciences targeting?
Who are IGM Biosciences' strategic partners?
What financial outlook has IGM Biosciences projected for 2023?
What is IGM-2323?
What is the IgM antibody technology platform?
What is the significance of IGM Biosciences' collaboration with Sanofi?
What recent developments have been made in IGM's pipeline?
What are IGM Biosciences' recent financial achievements?
